Contact | Print version | PDF version | Send article | RSS feed

Astex Announces New Drug Discovery Alliance with Janssen Pharmaceutica N.V.

11 Jun 2008 - Astex Therapeutics Limited announced that Astex and Janssen Pharmaceutica have entered into a research alliance focused on the research, development and commercialisation of novel drugs for the treatment of cancer. The new agreement grants Janssen Pharmaceutica a worldwide exclusive license to compounds arising from Astex's novel FGFR inhibitor programme, and the parties are also to establish a new drug discovery alliance focused on the identification of novel inhibitors against a further two cancer drug targets. The highly selective FGFR inhibitors were discovered using Astex's proprietary fragment-based drug discovery platform, Pyramid(TM), which will also be employed to drive the new drug discovery programme. Since 2004 Astex has used Pyramid(TM) to generate one new cancer drug candidate for clinical development each year.
 
Under the terms of the agreement, Ortho Biotech Research & Development, the research and development arm of Janssen Pharmaceutica, will be responsible for completing all of the pre-clinical and clinical development of all products arising from the collaboration and for their commercialisation globally. The agreement also grants Astex an option to co-commercialise FGFR products developed under the collaboration in the USA.
 
The agreement provides for an upfront payment and equity investment in Astex, plus committed research funding, totalling $37.4 million over a two year period, as well as downstream development and regulatory milestones relating to all three programmes. Astex will also receive tiered, double digit, royalties on sales of FGFR inhibitor products discovered and developed under the collaboration and additional royalties on new products generated under the other research programmes. Total payments under the collaboration, excluding royalties, could be worth over $500 million to Astex, assuming one product from each programme is successfully commercialised in all territories.